Home Limb Spasticity FDA Accepts Review of Botox for Pediatric Limb Spasticity

FDA Accepts Review of Botox for Pediatric Limb Spasticity

102
0

The Food and Drug Administration (FDA) has accepted supplemental Biologics License Applications (sBLA) for onabotulinumtoxinA (Botox) that seek to extend the drug label to include pediatric patients with upper and lower limb spasticity. If approved, the injection would be available for use in children 2 to 17 years of age in addition to the currently approved use in adults with upper and lower limb spasticity, reports MD Magazine.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.